Re: Durvalumab in Combination with BCG for BCG-naive, High risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial
Publication:
European Urology
© 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.